Pazopanib
As of the edition of 20 October 2026, Pazopanib is a small molecule: marketed, first approved in 2009 (US); acts on CSF1R, FLT1 and FLT4 and 5 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Votrient
- First approved
- 19 October 2009 (US)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- GSK; 3 holders in all
- Registered trials
- 251, 54 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Pazopanib.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| ITK | Tyrosine-protein kinase ITK/TSK | Q08881 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 8 | 1 | 2 |
| Phase 1 | 64 | 52 | 2 | 10 |
| Phase 2 | 153 | 95 | 13 | 38 |
| Phase 3 | 17 | 11 | 4 | 2 |
| Phase 4 | 5 | 2 | 0 | 2 |
| All trials | 251 |